Lymphoblastic Leukemia Clinical Trials

8 recruiting

Frequently Asked Questions

Common questions about Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 336 trials

Recruiting
Phase 3

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
National Cancer Institute (NCI)348 enrolled211 locationsNCT04530565
Recruiting
Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Acute Leukemia of Ambiguous LineageB Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)153 enrolled101 locationsNCT06317662
Recruiting
Not Applicable

A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...

Acute Lymphoblastic LeukemiaB-ALL
National Cancer Institute (NCI)60 enrolled8 locationsNCT05621291
Recruiting
Phase 1

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Leukemia, Lymphocytic, AcuteBlood CancerMyeloid Leukemia, Acute+8 more
National Cancer Institute (NCI)86 enrolled1 locationNCT06904066
Recruiting
Phase 1Phase 2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMixed Phenotype Acute Leukemia+2 more
Syndax Pharmaceuticals447 enrolled57 locationsNCT04065399
Recruiting
Phase 1

U69-CART-Cells For R/R T-ALL

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
The First Affiliated Hospital of Soochow University12 enrolled1 locationNCT07350863
Recruiting
Phase 2

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

T-cell Acute Lymphoblastic LeukemiaRecruiting
The First Affiliated Hospital of Soochow University28 enrolled1 locationNCT05376111
Recruiting
Phase 2

Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaTransplantation, Stem Cell+1 more
The First Affiliated Hospital of Soochow University48 enrolled1 locationNCT06816134
Recruiting
Phase 1Phase 2

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Acute LeukemiaLymphoblastic LymphomaLymphoblastic Leukemia
University of Chicago15 enrolled2 locationsNCT06207123
Recruiting
Phase 2

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoblastic LymphomaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
City of Hope Medical Center53 enrolled8 locationsNCT06918431
Recruiting
Phase 2

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Acute Lymphoblastic Leukemia ALL
Charite University, Berlin, Germany250 enrolled15 locationsNCT03590171
Recruiting
Not Applicable

Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy

Acute Lymphoblastic Leukemia
Hospital Universitario La Paz40 enrolled1 locationNCT07479927
Recruiting
Early Phase 1

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia
City of Hope Medical Center74 enrolled1 locationNCT03422731
Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults

ALL (Acute B-Lymphoblastic Leukemia)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology18 enrolled1 locationNCT07470073
Recruiting
Phase 3

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)222 enrolled134 locationsNCT06124157
Recruiting
Phase 1

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemias
Janssen Research & Development, LLC10 enrolled1 locationNCT07295951
Recruiting
Phase 2

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

T-cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic Lymphoma
M.D. Anderson Cancer Center22 enrolled1 locationNCT06561074
Recruiting
Phase 1

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

SarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaNeurofibroma, Plexiform+1 more
National Cancer Institute (NCI)54 enrolled1 locationNCT02390752
Recruiting
Phase 2

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)64 enrolled271 locationsNCT03739814
Recruiting
Phase 2

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
University of Washington30 enrolled1 locationNCT05453500